Icosavax Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Revenue	0	0.58	7.8	1.62	0
Revenue Growth (YoY)	-	-92.54%	382.80%	-	-
Gross Profit	0	0.58	7.8	1.62	0
Selling, General & Admin	35.84	30.23	34.89	2.66	1.24
Research & Development	70.04	65.41	38.78	17.67	4.16
Operating Expenses	105.88	95.64	73.66	20.33	5.4
Operating Income	-105.88	-95.06	-65.86	-18.71	-5.4
Interest Expense / Income	-1.52	-3.3	0.15	0.33	-0.1
Other Expense / Income	-7.65	-	0.96	-0.19	-
Pretax Income	-96.71	-91.76	-66.97	-18.85	-5.3
Net Income	-96.71	-91.76	-66.97	-18.85	-5.3
Preferred Dividends	0	0	0	0	0.67
Net Income Common	-96.71	-91.76	-66.97	-18.85	-5.97
Shares Outstanding (Basic)	50	40	18	2	7
Shares Outstanding (Diluted)	50	40	18	2	7
Shares Change	25.87%	121.11%	700.18%	-65.98%	-
EPS (Basic)	-2.22	-2.31	-3.73	-8.40	-0.90
EPS (Diluted)	-2.22	-2.31	-3.73	-8.40	-0.90
Free Cash Flow	-73.68	-72.79	-39.55	-14.22	-4.57
Free Cash Flow Per Share	-1.47	-1.83	-2.20	-6.33	-0.69
Gross Margin	-	100.00%	100.00%	100.00%	-
Operating Margin	-	-16332.99%	-844.16%	-1157.80%	-
Profit Margin	-	-15765.98%	-858.38%	-1166.71%	-
Free Cash Flow Margin	-	-12506.53%	-506.87%	-879.89%	-
EBITDA	-95.28	-93.22	-66.74	-18.52	-5.4
EBITDA Margin	-	-16016.32%	-855.40%	-1146.16%	-
Depreciation & Amortization	2.95	1.84	0.08	0	0
EBIT	-98.23	-95.06	-66.82	-18.52	-5.4
EBIT Margin	-	-16332.99%	-856.45%	-1146.23%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).